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Abstract
Rationale: Recently it has been shown that long-term intensive exercise practice is able to induce myocardial fibrosis in an
animal model. Angiotensin II is a profibrotic hormone that could be involved in the cardiac remodeling resulting from
endurance exercise.
Objective: This study examined the antifibrotic effect of losartan, an angiotensin II type 1 receptor antagonist, in an animal
model of heart fibrosis induced by long-term intense exercise.
Methods and Results: Male Wistar rats were randomly distributed into 4 experimental groups: Exercise, Exercise plus
losartan, Sedentary and Sedentary plus losartan. Exercise groups were conditioned to run vigorously for 16 weeks. Losartan
was orally administered daily before each training session (50 mg/kg/day). Time-matched sedentary rats served as controls.
After euthanasia, heart hypertrophy was evaluated by histological studies; ventricular collagen deposition was quantified by
histological and biochemical studies; and messenger RNA and protein expression of transforming growth factor-b1,
fibronectin-1, matrix metalloproteinase-2, tissue inhibitor of metalloproteinase-1, procollagen-I and procollagen-III was
evaluated in all 4 cardiac chambers. Daily intensive exercise caused hypertrophy in the left ventricular heart wall and
originated collagen deposition in the right ventricle. Additionally long-term intensive exercise induced a significant increase
in messenger RNA expression and protein synthesis of the major fibrotic markers in both atria and in the right ventricle.
Losartan treatment was able to reduce all increases in messenger RNA expression and protein levels caused by exercise,
although it could not completely reverse the heart hypertrophy.
Conclusions: Losartan treatment prevents the heart fibrosis induced by endurance exercise in training animals.
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Introduction
In recent years, a growing concern has arisen from numerous
observational studies reporting that long-term intense sport activity
could be associated with an increased risk of cardiac arrhythmias
[1–5]. In a previous study by our group we have demonstrated a
profibrotic cardiac remodeling following long-term intensive
exercise training in experimental animals, this could be the basis
for an increased arrythmogenicity in athletes [6]. In this respect, a
well designed recently published study, relates the presence of
myocardial fibrosis in veteran endurance athletes in the absence of
any other cause [7]. The etiology and clinical significance of these
findings have yet to be fully elucidated. Theres is therefore a need
for better understanding of the biological process involved and of
any upper limit above which intense exercise can be harmful to
health as well as the possibility of taking action to avoid this
damage.
Long-term exercise is associated with hemodynamic changes
and alters the loading conditions of the heart, these changes have
classically characterized the physiology of ‘‘athlete’s heart’’. It is
known that hemodynamic overload activates the renin-angiotensin
system (RAS) in the heart [8,9]. Although RAS plays an important
role in cardiovascular homeostasis by influencing vascular tone,
fluid and electrolyte balance, experimental evidence suggests that
RAS activation induces fibroblast proliferation and myocyte
hypertrophy [10,11]. Angiotensin II (ANGII) is produced by
proteolytic cleavage of its precursor angiotensin I by angiotensin
converting enzyme (ACE). ANGII plays an important role in
cardiac fibrogenesis [12] by acting as a potent grown factor and
cytokine for vascular smooth muscle cells, cardiac myocytes and
cardiac fibroblasts, via activation of the angiotensin type I receptor
(AT1) [13,14].
Losartan is a selective AT1 receptor antagonist. It has been
demonstrated that inhibition of cardiac RAS with ACE inhibitors
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and/or ANGII receptor blockers improves left ventricle function,
prevents geometric remodeling, and prolongs survival in several
heart diseases, such as hypertension, heart failure, ischemic heart
disease, and diabetes mellitus [15,16]. The antifibrotic effect of
losartan has also been described in other fibrotic processes such as
pulmonary fibrosis [17].
The main objective of this study was to evaluate the anti-fibrotic
effect of losartan in an animal model of heart fibrosis induced by
chronic endurance exercise. Our results showed that losartan was




This study conformed to European Community (Directive 86/
609/EEC) and Spanish guidelines for the use of experimental
animals and it was approved by the institutional committees of
animal care and research. 24 pathogen-free, 4 week old, male
Wistar rats, weighing 100–125 g at the beginning of experiments
(Charles River Laboratories, France), were housed in a controlled
environment (12 : 12-h light-dark cycle), and fed rodent chow
(A04; Panlab, Barcelona, Spain) and tap water ad libitum.
Experimental groups. Animals were randomly distributed
into four experimental groups:
Sedentary n~12ð Þ
Sedentaryzlosartan SedentaryzLOSð Þ n~12ð Þ
Exercise n~12ð Þ
Exercisezlosartan ExercisezLOSð Þ n~12ð Þ
The exercise protocol was performed as in our previous study [6].
Briefly, exercise rats underwent a daily running session on a
treadmill (Panlab, Barcelona, Spain) five days a week for 16 weeks.
Losartan (50 mg/kg/day) was administered orally, every day at
the same hour, starting in the first exercise session and continuing
up to the end of the experiment. The drug was dissolved in a final
volume of 1,5 ml of distilled water. Oral administration was
selected as this is the usual method in a clinical setting. The first
exercise session lasted for 10 min at 25 cm/s, and the duration
and intensity were gradually increased reaching 60 min at 60 cm/
s on the 10th day these levels were then maintained until the end of
training. The animals were euthanized three days after the end of
the training program to avoid any immediate responses. The
hearts were quickly removed, weighed, dissected into left ventricle
(LV), right ventricle (RV), left atrium (LA) and right atrium (RA);
they were then frozen in liquid nitrogen for storage at 280uC until
analyzed (n = 6, for each group), or fixed for histological studies
(n = 6, for each group).
Cardiac hypertrophy
Cardiac hypertrophy was assessed by determining the heart-
weight to body-weight ratio and by measuring the ventricular wall
thickness at papillary muscle levels. To measure the wall thickness
from RV free wall (RV FW), interventricular septum (IV), and LV
free wall (LV FW), 12 measurements from each wall were taken
per animal in heart paraffin sections using analySIS Image
Processing software (Soft Imaging System GMBH, Germany)
(Fig. 1A). Differences in ventricular size were controlled by
indexing wall-thickness to body-weight.
Histology and morphometry
For the histological studies, the heart was perfused with a
fixative solution (10% neutral-buffered formalin) at a pressure of
80 cm H2O, immersed in the fixative for 12–24 h, and embedded
in paraffin. Sections were cut at 4 mm thick serial sections and
stained with Picrosirius red to identify connective tissue and
collagen deposition. Additionally, sections from the RV were
stained with picrosirius-red to quantify of collagen deposition using
analySIS Image Processing software (Soft Imaging System
GMBH, Germany) as previously described [6]. Perivascular
collagen was excluded from this measurement.
mRNA analysis
Total RNA was extracted from 50 to 100 mg of a section of the
LV, RV, LA and RA using TrizolH reagent (Invitrogen
Corporation, CA, USA) according to the manufacturer’s protocol.
RNA integrity and loading amounts were assessed by examining
UV/VIS at multiple wave lengths following the ND-3300 user
manual V2.5, instructions (ND-3300, NanoDrop Technologies,
USA). Analysis of transforming growth factor-b1 (TGF-b1),
fibronectin-1, metalloproteinase 2 (MMP-2), tissue inhibitor of
metalloproteinase 1 (TIMP-1), procollagen-1 (Proc-I) and procol-
lagen-3 (Proc-III) mRNA expression was obtained by Real-Time
PCR. One mg total mRNA was converted to cDNA with the
iScript cDNA (Bio-Rad Laboratories, CA, USA), according to the
manufacturer’s protocol. 100 ng of cDNA was amplified by the
iCycler IQTM version 3.1 (Bio-Rad Laboratories, CA, USA) using
Applied Biosystems (Applied Biosystems, CA, USA) TaqMan gene
expression assays (Rn00572010-m1 for TGF-b1, Rn00569575-m1
for fibronectin-1, Rn02532334-s1 for MMP-2, Rn00587558-m1
Figure 1. Assessment of ventricular hypertrophy. (A) Represen-
tative graph of a tissue slice indicating the three areas of study: right
ventricular free wall (RV FW), left ventricular free wall (LV FW) and
interventricular septum (IVS). Twelve measures were obtained from
each of the areas. (B) Results of ventricular wall thickness indexed for
body weight in all the experimental groups. LV FW was significantly
higher in all exercise groups compared to sedentary groups. Data are
means 6 SEM of 6 (sedentary and sedentary+LOS) and 6 (exercise and
exercise+LOS). * p,0.05 sedentary vs exercise; $ p,0.05 sedentary+LOS
vs exercise+LOS, and, # p,0.05 exercise vs exercise+LOS.
doi:10.1371/journal.pone.0055427.g001
Losartan Prevents Exercise-Induced Heart Fibrosis
PLOS ONE | www.plosone.org 2 February 2013 | Volume 8 | Issue 2 | e55427
for TIMP-1, Rn01526721-m1 for procollagen-1, Rn01437675-m1
for procollagen-3 and Rn00667869-m1 for actin, which was used
as a housekeeping reference). Data was analyzed with the DCt
method.
SDS-PAGE and Western blot
Protein samples were extracted using Nonidet P-40 buffer. SDS-
PAGE was performed on 5%–13% acrylamide gels. Proteins were
electrotransferred to nitrocellulose membrane and probed with
primary antibodies. The antibodies used included mouse mono-
clonal anti-TGF-b1 (ab27969, dilution1/2000), mouse monoclo-
nal anti-MMP2 (ab7032 dilution 1/1000), rabbit polyclonal to
TIMP1 (ab61224 dilution 1/1000), mouse monoclonal to colla-
gen-I (ab6308 dilution 1/1000) (all of them acquired from Abcam
plc, Cambridge, UK); rabbit polyclonal antifibronectin (BP8025,
dilution 1/1000) (Acris Antibodies GmbH, Herford, Germany)
and rabbit polyclonal to collagen-III (dilution 1/500) (Santa Cruz
Biotechnology, Ca, USA), and mouse monoclonal anti-actin
(dilution (1/1000) (Chemicon-Millipore Co, MA, USA), which
served as a housekeeping reference. The membranes were
incubated with the corresponding peroxidase-conjugated second-
ary antibodies, washed, and then incubated with ECL reagents
(GE Healthcare Europe GmbH; Freigburg; GE) before exposure
to high-performance chemiluminescence films. Gels were calibrat-
ed using Bio-Rad standard proteins (Hercules, CA) with markers
covering a 7–240 kDa range. Films were scanned by using image-
editing software NIH ImageJ software for densitometric analysis of
immunoreactive bands.
Statistical analysis
Data is expressed as mean 6 SEM values with 95% confidence
intervals. Statistical analysis was carried out by analysis of variance
(ANOVA) followed by appropriate post-hoc tests, including
Bonferroni correction and unpaired t-test. (GraphPad Software




Exercise causes a significant body weight loss in both exercise
groups. Losartan treatment did not modify the body weight loss.
Heart weight did not show any significant differences between all
the study groups. However, the heart-weight-to-body-weight ratio
was significantly different between exercise groups and sedentary
groups. The body and heart weight, and the ratio between body
and heart weight are summarized in Table 1.
Direct measurements of wall thickness confirmed significant
increments in IV and LV FW in the exercised groups compared to
their respective sedentary groups, exercise+LOS shows a reduction
in the LV FW thickening compared to exercise group, although
the exercise+LOS remained significantly increased relative to LOS
alone. No significant differences were observed in RV FW
thickness (Fig. 1B).
Histopathology
To further examine the effect of exercise heart serial sections
were stained with Picrosirius red to identify collagen deposition,
and examined by light microscopy. Diffuse interstitial collagen
deposition associated with disturbances in myocardial architecture
was observed only in the exercise group (Fig. 2A). Additionally,
morphometric quantification in RV confirmed a significant
increase in collagen deposition only in the exercise group. No
differences in collagen density were observed in the exercise+LOS
group. (Fig. 2 B)
mRNA analysis
Messenger RNA (mRNA) expression of TGFb-1, fibronectin-1,
MMP-2, TIMP-1, procollagen-1 and prollagen-3 was measured in
all cardiac chambers of rats in all the different groups under study.
TGFb-1 expression was significantly increased in the RA of
exercise and exercise+LOS compared to its respective sedentary
groups, although the increase observed in the exercise+LOS group
were significantly reduced compared to that of the exercise group
(Figure 3A). Furthermore, TGF-b1 expression was also signifi-
cantly increased in the LA and RV in only the exercise group
compared to the sedentary group, while exercise+LOS did not
show any significant differences compared to its sedentary group
(Figure 3A).
Fibronectin-1 expression was significantly increased in RA and
RV of exercise and exercise+LOS, compared to its respective
sedentary groups, although the increase showed by exercise+LOS
was significantly reduced compared to the exercise group
(Figure 3B). Fibronectin-1 expression was also increased in the
LA in only the exercise group compared to the sedentary group,
while exercise+LOS did not show any significant differences
compared to its sedentary group.
Finally, MMP-2, TIMP-1, procollagen-I and procollagen-III
mRNA expression was significantly increased in the RA, LA and
RV only in the exercise group, while its expression in the
exercise+LOS group was similar to that of the control groups
(Figure 3C, 3D, 3E and 3F).
Western blot analysis
Alterations in protein expression corresponding to mRNA
changes were assessed by Western blot analysis for TGF-b1,
fibronectin-1, MMP-2, TIMP1, collagen-I, and collagen-III.
Table 1. Body weights, heart weights and heart weight/body weight ratios at the endpoint.
Body Weight Heart Weight Heart Weight/Body Weight (61000)
Sedentary 414.8613.98 1.02760.090 0.0024460.00009
Sedentary+LOS 382.5617.97 0.94060.090 0.0024560.00025
Exercise 357.168.25* 1.11860.050 0.0030860.00006*
Exercise+LOS 339.768.96{ 1.02560.042 0.0031260.00004{
Groups: Sedentary; Exercise, Sedentary+LOS = sedentary plus losartan; Exercise+LOS = exercise plus losartan. BW = body weight; HW = heart weight; HW/BW = heart
weight-to-body weight ratio. Data are mean 6 SEM of 6 animals (sedentary and sedentary+LOS) and 6 animals (exercise and exercise+LOS).
*p,0.05 exercise group vs sedentary group and
{p,0.05 sedentary+LOS vs exercise+LOS.
doi:10.1371/journal.pone.0055427.t001
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TGF-b1 protein levels were significantly increased in both atria
and in the RV of exercised rats. Exercise+LOS group showed
similar levels to the sedentary groups (Figure 4A).
Fibronectin-1 protein levels showed significant increases in RA,
LA and RV in the exercise group, while the exercise+LOS group
showed the same patterns of protein levels as the sedentary groups
(Figure 4B).
MMP-2 protein synthesis was significantly increased in the RA
and in the LA of the exercise group, whereas the synthesis levels
for MMP-2 did not show any differences between the exercise+-
LOS and the sedentary groups (Figure 4C).
TIMP1 showed increased synthesis in the RA, LA and RV of
the exercise group, losartan treatment was able to avoid such
increases in the exercise+LOS group (Figure 4D).
Collagen-I protein levels were significantly greater in the RA,
LA and RV of the exercise group; exercise+LOS showed protein
levels similar to those of sedentary group (Figure 4E).
Finally, collagen-III protein levels showed an increase in the
exercise group in RA, LA and RV, while the exercise+LOS group
showed the same protein levels as the sedentary groups (Figure 4F).
Overall these results confirm the development of significant
changes in the extracellular matrix (ECM) changes after 16 weeks
of intensive endurance exercise, with a clear fibrosis development
in the RV but not the LV, while also corfirming the effectiveness of
losartan treatment in preventing this pathological remodeling.
Discussion
We have shown that losartan, a selective AT1 receptor
antagonist, ameliorates experimental exercise-induced myocardial
fibrosis. Our findings provide further evidence for the anti-fibrotic
effect of losartan.
Chronic exercise induces hemodynamic changes and alters the
loading conditions of the heart [6], thus generating structural
cardiac adaptations that are considered physiological, (and
commonly known as athlete’s heart) [18]. Long-term volume
and pressure overloads, caused by intense exercise, can induce
cardiac maladaptative responses including remodeling and fibro-
sis, which ultimately lead to heart tissue dysfunction similar to that
found in pathological conditions of chronic overload such as heart
failure and hypertension [19,20]. Several studies with animal
models of acute exercise have shown histological evidence of
reactive scar tissue formation and elevation of necrosis and fibrosis
markers immediately following intense exercise [21,22]. Further-
more, Lindsay et al have found biochemical evidence of
myocardial fibrosis in veteran endurance athletes [23]. Also, in a
previous animal model we have demonstrated the direct relation-
ship between a long-term endurance exercise schedule and the
development of myocardial fibrosis and increased arrhythmia
inducibility [6]. In this study, the progressive alteration in ECM
composition induced by exercise increased myocardial stiffness,
promoted the development of diastolic dysfunction and became a
potential substrate for the development of arrhythmias [6]. It is
particularly noteworthy that our findings in an animal model were
similar to those observed in a study on veteran endurance athletes
[7].
The present results confirm that 16 weeks of endurance exercise
training in rats promotes left ventricular hypertrophy [6].
Furthermore, exercised animals developed myocardial fibrosis
and showed alterations in ECM protein synthesis in both atria and
in the right ventricle, indicating that these changes could promote
alterations in heart functionality [6]. Therefore, ameliorating and
preventing myocardial fibrosis would be very important in the
management of future cardiovascular events [24,25]. ANGII is a
powerful stimulus for progressive cardiac remodeling and plays a
significant role in promoting myocardial fibrosis [26,27]. AT1
receptor antagonists have antifibrotic and anti-growth effects on
the myocardium in experimental settings [28,29]. It has been
reported that circulating ANG II plays a central role in the
progression of myocardial fibrosis and hypertrophy in hypertensive
patients [30,31].
As described in with previous works [6,32], our results also
showed an increased cardiac mass and left ventricular hypertro-
phy, reflecting the enlargement of the left ventricular cavity that
following long-term endurance training and that is considered
typical of the athlete’s heart [18]. Left ventricular hypertrophy as
detected by echocardiogram is an independent predictor of
morbidity and mortality in subjects with high blood pressure
[33] and in the population at large [34]. In the literature, there are
several studies evaluating the therapeutic benefits of ACE
inhibitors or the intervention of AT1 antagonists in reducing left
Figure 2. Assessment of right ventricle myocardial fibrosis. (A)
Representative Picrosirius red-stained photomicrographs of the right
ventricle, S: sedentary; S+LOS: sedentary plus losartan; E: exercise;
E+LOS: exercise+losartan. Magnification 6200. An excess of interstitial
collagen deposition (red staining) was observed in the right ventricle of
the exercise group. (B) Morphometryc analysis of collagen deposition.
Mean 6 SEM collagen content in RV. * p,0.05 sedentary vs exercise, #
p,0.05 exercise vs exercise+LOS.
doi:10.1371/journal.pone.0055427.g002
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ventricular hypertrophy [35,36]. In agreement with these studies,
our findings show that losartan treatment was able to partially
prevent left ventricular hypertrophy in exercised animals. One
interesting observation is the fact that the development of
hypertrophy is observed in the LV, but the increases in both the
expression and the synthesis of fibrotic markers are observed in the
RA, LA and RV. This could be explained by the intrinsic features
of these cavities, including their thinner walls, which could make
them more susceptible to damage from heart volume and pressure
overload induced by exercise. In contrast, the LV structure is
thicker and responds to pressure and volume overload by
increasing its thickness even further, thus demonstrating greater
resistance to changes in the composition of the ECM. Cardiac
remodeling in response to hemodynamic stress and/or injury
includes changes in the cardiomyocyte compartment as well as the
nonmyocyte compartment (endothelial cells, vascular smooth
muscle cells, macrophages, and cardiac fibroblasts). Pathological
changes in cardiac remodeling include myocyte hypertrophy,
myocyte death, and dynamic changes in the interstitium.
Interstitial changes involve qualitative and quantitative alterations
in the fibrillar collagen network (composed mainly of types I and
III fibrillar collagen), including changes in collagen cross-linking
[37]. Collagen-I determines the stiffness of cardiac muscle,
whereas collagen-III is more distensible. Thus, the ratio of
collagen-I to collagen-III can be a marker of the ECM
determinants of cardiac stiffness [38]. We observed a significant
Figure 3. mRNA expression of fibrosis markers in each of the four cardiac chambers. Results are expressed according to the DCt method,
with exercise group values in reference to those of the sedentary group (DCt 6 SEM). Data are means 6 SEM of 4 animals (all groups). * p,0.05
sedentary vs exercise; $ p,0.05 sedentary+LOS vs exercise+LOS, and, # p,0.05 exercise vs exercise+LOS.
doi:10.1371/journal.pone.0055427.g003
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increase in collagen-I and III protein expression in the RV in the
exercise group, where collagen-I expression was more prominent,
indicating that long-term, intensive exercise could increase cardiac
stiffness. Losartan treatment was able to avoirevent all the
increases in fibrotic markers caused by endurance exercise,
thereby preventing myocardial ECM remodeling. The antifibrotic
effect of AT1 receptor blockade has been reported in other studies
[29,39]. Our findings agree with those of Chen et al [37], who
showed that an AT1 receptor antagonist prevented the early
induction of TGF-b1 and the subsequent development of cardiac
fibrosis, indicating that ANG II acts indirectly through the
expression of TGF-b1 to induce cardiac fibrosis. It has been
proposed that a phenotypic change from the cardiac fibroblast to
the more synthetic myofibroblast phenotype takes place under the
influence of cytokines such as TGF-b1, promoting the deposition
of collagen [40]. Myocardial collagen content is tightly regulated
by a balance between collagen production and degradation.
Extracellular degradation of collagen is the most important brake
on collagen metabolism and it is effected by matrix metallopro-
teinases (MMPs) [41]. The intramyocardial coronary arterioles
also undergo changes in cardiac remodeling resulting in medial
thickening and perivascular fibrosis. Collectively these changes
lead to progressive impairment of the cardiac function. Our results
showed a significant increase in mRNA expression for TGF-b1,
MMP-2, TIMP-1, fibronectin-1, collagen type I and collagen type
III as a consequence of intense and long-lasting exercise. Losartan
treatment was able to bring all these increases down to control
levels in this animal model, indicating the beneficial effect of
blocking the RAS system in preventing on myocardial remodeling
resulting from intense exercise.
In summary, this study demonstrates that losartan treatment in
exercised animals prevents the heart fibrosis induced by endurance
exercise and strengthens the recent theory that intense exercise
could be associated with left ventricular hypertrophy and
interstitial myocardial fibrosis [6,7,23,42]. This finding opens up
the possibility of using losartan as a treatment for preventing of the
heart’s maladaptative responses to long-term intense exercise.
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